AbbVie expects $12.7 billion in neuroscience sales this year
AbbVie’s neuroscience portfolio is expected to generate $12.7 billion in revenue this year.
The company’s neuroscience business has become increasingly diversified, with growth coming from multiple products.
During the second quarter, neuroscience revenue climbed 20.3% year over year to $3.23 billion, driven by strong sales of Vraylar, Botox, and migraine drugs.